FGFR4 and hepatocellular carcinoma: Using multikinase inhibitors such as lenvatinib in patients with HCC can silence FGFR4, thereby inhibiting the expression of the xCT system, inducing the accumulation of ROS, and causing ferroptosis in HCC cells (Iseda et al., 2022).